The effect of ulinastatin on postoperative blood loss in patients undergoing open heart surgery with cardiopulmonary bypass

Journal of International Medical Research

Volumn 39, Issue 4, 2011, Pages 1201-1210

  Song, J E ^a   Kang, W S ^a   Kim, D K ^a   Yoon, T G ^a   Kim, T Y ^a   Bang, Y S ^b   Kim, S H ^a  

^a Konkuk University School of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

Cardiopulmonary bypass; Polymorphonuclear neutrophils (PMNs); Postoperative blood loss; Transfusion; Ulinastatin

Indexed keywords

PLACEBO; SODIUM CHLORIDE; ULINASTATIN; ULISTIN; UNCLASSIFIED DRUG;

ADULT; AGED; AORTA CLAMPING; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INTENSIVE CARE UNIT; INTUBATION; LENGTH OF STAY; LEUKOCYTE; MALE; MULTIPLE ORGAN FAILURE; NEUTROPHIL; OPEN HEART SURGERY; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT DURATION;

EID: 80052224208     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900408     Document Type: Article

References (37)

1. Cremer J, Martin M, Redl H, et al: Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996; 61: 1714-1720.
2. Asimakopoulos G: Systemic inflammation and cardiac surgery: an update. Perfusion 2001; 16: 33-60.
3. Schwartz SM, Duffy JY, Pearl JM, et al: Cellular and molecular aspects of myocardial dysfunction. Crit Care Med 2001; 29(10 suppl): S214-S219.
4. Doguet F, Litzler PY, Tamion F, et al: Changes in mesenteric vascular reactivity and inflammatory response after cardiopulmonary bypass in a rat model. Ann Thorac Surg 2004; 77: 2130-2137.
5. Murphy GJ, Angelini GD: Side effects of cardiopulmonary bypass: what is the reality? J Card Surg 2004; 19: 481-488.
6. Grocott HP, Stafford-Smith M: Organ protection during cardiopulmonary bypass. In: Kaplan's Cardiac Anesthesia, 5th edn (Kaplan JA, Reich DL, Lake CL, et al, eds). Philadelphia: Elsevier Health Sciences; 2006; pp 985-1022.
7. Hansen PR: Role of neutrophils in myocardial ischemia and reperfusion. Circulation 1995; 91: 1872-1885.
8. Kope M, Bykowska K, Lopaciuk S, et al: Effects of neutral proteases from human leukocytes on structure and biological properties of human factor VIII. Thromb Haemost 1980; 43: 211-217.
9. Taki M, Miura T, Inagaki M, et al: Influence of granulocyte elastase-like proteinase (ELP) on platelet functions. Thromb Res 1986; 41: 837-846.
10. Björk P, Axelsson L, Bergenfeldt M, et al: Influence of plasma protease inhibitors and the secretory leucocyte protease inhibitor on leucocyte elastase-induced consumption of selected plasma proteins in vitro in man. Scand J Clin Lab Invest 1988; 48: 205-211.
11. Manfredi AA, Rovere-Querini P, Maugeri N: Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr Opin Hematol 2010; 17: 3-8.
12. Muramatu M, Mori S, Matsuzawa Y, et al: Purification and characterization of urinary trypsin inhibitor, UTI68, from normal human urine, and its cleavage by human uropepsin. J Biochem 1980; 88: 1317-1329.
13. Ogawa M, Nishibe S, Mori T, et al: Effect of human urinary trypsin inhibitor on granulocyte elastase activity. Res Commun Chem Pathol Pharmacol 1987; 55: 271-274.
14. Ohnishi H, Suzuki K, Niho T, et al: Protective effects of urinary trypsin inhibitor in experimental shock. Jpn J Pharmacol 1985; 39: 137-144.
15. Okida M, Masako O, Maruya H, et al: Intraoperative changes in blood coagulation and the effectiveness of ulinastatin during liver resection. J Anesth 1991; 5: 43-47.
16. Ji HW, Chen L: Effects of ulinastatin on coagulation and platelet function in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Zhonghua Yi Xue Za Zhi 2009; 89: 175-178 [in Chinese, English abstract].
17. Schnider TW, Minto CF, Shafer SL, et al: The influence of age on propofol pharmacodynamics. Anesthesiology 1999; 90: 1502-1516.
18. Minto CF, Schnider TW, Shafer SL: Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application. Anesthesiology 1997; 86: 24-33.
19. De Hert SG, Van der Linden PJ, Cromheecke S, et al: Choice of primary anesthetic regimen can influence intensive care unit length of stay after coronary surgery with cardiopulmonary bypass. Anesthesiology 2004; 101: 9-20.
20. Lee JY, Lee JY, Chon JY, et al: The effect of ulinastatin on hemostasis in major orthopedic surgery. Korean J Anesthesiol 2010; 58: 25-30.
21. Nishiyama T, Aibiki M, Hanaoka K: The effect of ulinastatin, a human protease inhibitor, on the transfusion-induced increase of plasma polymorphonuclear granulocyte elastase. Anesth Analg 1996; 82: 108-112.
22. Butler J, Rocker GM, Westaby S: Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 552-559.
23. Wan S, LeClerc JL, Vincent JL: Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997; 112: 676-692.
24. Hu XH, Zhang HY, Ge YL, et al: Protective effects of ulinastatin against multiple organ damage after severe burn injury: experimental and clinical studies. Zhonghua Yi Xue Za Zhi 2005; 85: 2889-2894 [in Chinese, English abstract].
25. Tsujino T, Komatsu Y, Isayama H, et al: Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005; 3: 376-383.
26. Davis R, Whittington R: Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995; 49: 954-983.
27. Mangano DT, Tudor I, Dietzel C, et al: The risk associated with aprotonin in cardiac surgery. N Engl J Med 2006; 354: 353-365.
28. Mangano DT, Miao Y, Vuylsteke A, et al: Mortality associated with aprotonin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297: 471-479.
29. Sodha NR, Boodhwani M, Sellke FW: Is there still a role for aprotonin in cardiac surgery? Drug Saf 2007; 30: 731-740.
30. Fergusson DA, Hébert PC, Mazer CD, et al: A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-2331.
31. Henry D, Carless P, Fergusson D, et al: The safety of aprotonin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009; 180: 183-193.
32. Nakanishi K, Takeda S, Sakamoto A, et al: Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006; 34: 1351-1357.
33. Hiyama A, Takeda J, Kotake Y, et al: A human urinary protease inhibitor (ulinastatin) inhibits neutrophil extracellular release of elastase during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 580-584.
34. Bingyang J, Jinping L, Mingzheng L, et al: Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularisation. Effect of ulinastatin on inflammatory response. J Cardiovasc Surg (Torino) 2007; 48: 497-503.
35. Takada K, Komori M, Notoya A, et al: Effect of ulinastatin on microcirculation during excessive hemorrhage using fluid therapy. In Vivo 2003; 17: 129-135.
36. Kurosawa S, Kanaya N, Fujimura N, et al: Effects of ulinastatin on pulmonary artery pressure during abdominal aortic aneurysmectomy. J Clin Anesth 2006; 18: 18-23.
37. Heimrath OP, Buth KJ, Légaré JF: Long-term outcomes in patients requiring stay of more than 48 hours in the intensive care unit following coronary bypass surgery. J Crit Care 2007; 22: 153-158.